PCI unveiled its new brand identity at CPhI Worldwide 2015 this week, signalling the full integration of Penn Pharma and Biotec Services International
PCI's ‘molecule to market’ pharmaceutical processes takes compounds from the earliest stages of development through to launch
All parts of the PCI organisation will now operate under the PCI Pharma Services name and brand.
Bill Mitchell, PCI president and chief executive officer, said: “We strive to position PCI to best support our clients in bringing new medicines to successful commercialisation.
“The new brand is reflective of the expanded scope of services and the partnership we enjoy with our clients.”
The combined PCI business delivers ‘molecule to market’ pharmaceutical processes that take compounds from the earliest stages of development through to successful launch and ongoing supply.
Mitchell said: “Since its creation in 2013, PCI has focused on strategic investments and acquisitions with a strategy to best support our client needs with a model of industry-leading expertise, world-class facilities, and cutting edge technologies.
“This unique blend enables us to address evolving global drug development needs at each stage of the product lifecycle.”
